Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 2,930,000 shares, an increase of 26.3% from the February 13th total of 2,320,000 shares. Currently, 5.8% of the company’s stock are short sold. Based on an average daily volume of 1,000,000 shares, the days-to-cover ratio is presently 2.9 days.
Charles River Laboratories International Price Performance
Shares of Charles River Laboratories International stock traded up $2.01 on Tuesday, reaching $177.02. The stock had a trading volume of 1,011,890 shares, compared to its average volume of 711,526. Charles River Laboratories International has a 1 year low of $150.79 and a 1 year high of $274.77. The company has a market cap of $9.05 billion, a P/E ratio of 1,180.13, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The business’s 50 day moving average is $167.46 and its two-hundred day moving average is $184.33.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the firm posted $2.46 earnings per share. The company’s revenue for the quarter was down 1.1% on a year-over-year basis. As a group, research analysts anticipate that Charles River Laboratories International will post 9.36 EPS for the current year.
Insider Activity at Charles River Laboratories International
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of CRL. Wellington Management Group LLP increased its position in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. D1 Capital Partners L.P. bought a new position in shares of Charles River Laboratories International in the fourth quarter worth approximately $172,752,000. Norges Bank bought a new position in shares of Charles River Laboratories International in the fourth quarter worth approximately $98,886,000. Nomura Holdings Inc. bought a new position in shares of Charles River Laboratories International in the fourth quarter worth approximately $56,820,000. Finally, Raymond James Financial Inc. bought a new position in shares of Charles River Laboratories International in the fourth quarter worth approximately $42,776,000. 98.91% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts recently weighed in on the stock. Citigroup raised shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and boosted their price target for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Robert W. Baird cut their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. Morgan Stanley cut their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Finally, UBS Group reissued a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $198.36.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- 5 discounted opportunities for dividend growth investors
- 3 Must-Own Stocks to Build Wealth This Decade
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.